Blue Trust Inc. purchased a new position in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 21,172 shares of the company's stock, valued at approximately $466,000.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. FMR LLC boosted its position in shares of Cellebrite DI by 136.3% in the third quarter. FMR LLC now owns 5,616,757 shares of the company's stock worth $94,586,000 after buying an additional 3,239,307 shares during the period. Meitav Investment House Ltd. boosted its position in Cellebrite DI by 29.7% during the 3rd quarter. Meitav Investment House Ltd. now owns 2,066,322 shares of the company's stock worth $34,797,000 after acquiring an additional 473,293 shares during the period. Pembroke Management LTD boosted its position in Cellebrite DI by 24.3% during the 3rd quarter. Pembroke Management LTD now owns 1,908,345 shares of the company's stock worth $32,137,000 after acquiring an additional 372,619 shares during the period. Principal Financial Group Inc. purchased a new position in Cellebrite DI during the 3rd quarter valued at about $23,402,000. Finally, Two Sigma Advisers LP increased its holdings in shares of Cellebrite DI by 9.8% in the 3rd quarter. Two Sigma Advisers LP now owns 1,341,100 shares of the company's stock valued at $22,584,000 after purchasing an additional 120,000 shares during the period. Institutional investors and hedge funds own 45.88% of the company's stock.
Analyst Ratings Changes
A number of research analysts recently commented on CLBT shares. JPMorgan Chase & Co. boosted their price objective on shares of Cellebrite DI from $22.00 to $24.00 and gave the company an "overweight" rating in a research report on Monday, December 16th. Craig Hallum boosted their price target on shares of Cellebrite DI from $23.00 to $24.00 and gave the company a "buy" rating in a report on Thursday, November 7th. Finally, Needham & Company LLC increased their price objective on Cellebrite DI from $21.00 to $28.00 and gave the stock a "buy" rating in a report on Wednesday, January 22nd. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $21.57.
View Our Latest Analysis on Cellebrite DI
Cellebrite DI Price Performance
NASDAQ:CLBT traded up $0.79 during trading hours on Tuesday, reaching $25.46. The company's stock had a trading volume of 2,996,614 shares, compared to its average volume of 1,638,140. The company has a market cap of $5.24 billion, a price-to-earnings ratio of -16.43, a price-to-earnings-growth ratio of 3.55 and a beta of 1.47. Cellebrite DI Ltd. has a one year low of $8.91 and a one year high of $25.95. The business's 50-day moving average is $21.87 and its 200-day moving average is $18.54.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.05. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. The company had revenue of $106.90 million during the quarter, compared to the consensus estimate of $102.06 million. During the same quarter in the prior year, the company posted $0.09 EPS. The firm's revenue was up 27.0% on a year-over-year basis. On average, sell-side analysts predict that Cellebrite DI Ltd. will post 0.32 EPS for the current fiscal year.
Cellebrite DI Profile
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Further Reading
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
